Biofourmis

Biofourmis describes itself as a connected technology platform company that partners with health systems, hospitals, payers, risk-bearing organizations, and life science companies to revolutionize drug life cycle management and the delivery of care across the continuum. Its technology-enabled solutions aim to make home a site of care, with offerings including Hospital at Home, Timely Discharge, SNF at home, and Remote Patient Management. The company states that outcomes have shown clinical, operational, and economic improvements such as a 70% reduction in 30-day readmissions, the ability to detect deterioration 21 hours sooner, and reductions in cost of care by up to 38%. Its platform uses biosensor data collection, FDA-cleared AI-enabled analytics, and dynamic care pathways. Biofourmis reports being licensed to provide care in 25 states and having served more than 150,000 patients. A merger announcement on its site states that CopilotIQ and Biofourmis merged to create an end-to-end platform for AI-driven in-home care. The company lists global offices in Boston, Singapore, and India, and its executive team includes CEO David Koretz.

Biofourmis describes itself as a connected technology platform company that partners with health systems, hospitals, payers, risk-bearing organizations, and life science companies to revolutionize drug life cycle management and the delivery of care across the continuum. Its solutions are designed to deliver and transition patients across levels of care, with the stated goal of making home a site of care. The company reports that outcomes have shown clinical, operational, and economic improvements such as a 70% reduction in 30-day readmissions, the ability to detect deterioration 21 hours sooner, and reductions in cost of care by up to 38%. Its platform collects and aggregates biosensor data, uses FDA-cleared algorithms to detect and predict clinical deviation, and facilitates personalized interventions through dynamic care pathways. Biofourmis states it is licensed to provide care in 25 states and has served more than 150,000 patients. A merger announcement on its website states that CopilotIQ and Biofourmis merged to create the first end-to-end platform for AI-driven in-home care. The company lists global offices in Boston, Singapore, and India.

Biofourmis positions itself as a partner to health systems, hospitals, payers, risk-bearing organizations, and life science companies, aiming to make home a site of care and to deliver care across the continuum.

• Hospital at Home

• Timely Discharge

• SNF at home

• Remote Patient Management

• 2020.04.16

  Reported2020.04.16

  Biofourmis announces agreement to acquire Gaido Health[6]Biofourmis 宣布达成收购 Gaido Health 的协议prnewswire.com

  Biofourmis announced that it had finalized an agreement to acquire Gaido Health from Takeda Pharmaceuticals. The announced deal would expand Biofourmis' oncology digital-therapeutics portfolio.

• 2020.01.30

  Reported2020.01.30

  Biofourmis and ImagineMIC announce remote patient-monitoring partnership[7]Biofourmis与ImagineMIC宣布远程患者监测合作prnewswire.com

  Biofourmis and ImagineMIC announced a partnership to combine Biofourmis’ RhythmAnalytics with ImagineMIC’s remote-management technology, initially supporting clinical monitoring for patients with chronic conditions.

Read more

1. 1Biofourmis | Revolutionize the delivery of carebiofourmis.com
2. 2Biofourmis | Leaders in the future of healthbiofourmis.com
3. 3Platformbiofourmis.com
4. 4Biofourmis | Technology-enabled care deliverybiofourmis.com
5. 5Biofourmis (United States)wikidata.org
6. 6Biofourmis 宣布达成收购 Gaido Health 的协议prnewswire.com
7. 7Biofourmis与ImagineMIC宣布远程患者监测合作prnewswire.com